Edwards’ Q3 revenues were chiefly driven by a 12.4% uplift in its transcatheter aortic valve replacement (TAVR) product group to $1.14bn, up from around $1bn in Q3 2024. Image credit: Steve Cukrov via Shutterstock.com.

Edwards Lifesciences has raised its fiscal year (FY25) guidance to between $2.56 to $2.62 per share after achieving better than expected revenues in the third quarter (Q3).

The company achieved sales growth of 14.7% to around $1.55bn in Q3. Edwards now expects FY25 sales growth to come in at the high end of 9% to 10%, with its share price guidance of $2.56 to $2.62 up from the $2.45 to $2.55 range forecast previously.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Edwards’ Q3 revenues were chiefly driven by a 12.4% uplift in its transcatheter aortic valve replacement (TAVR) product group to $1.14bn, up from around $1bn in Q3 2024.

TAVR has long been a dominant revenue driver for Edwards, with the life sciences giant recently sharing seven-year data on its SAPIEN 3 TAVR system at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco.

Presented during a late-breaking session at TCT, data from Edwards’ PARTNER 3 (NCT02675114) trial reaffirmed the early and sustained benefit of SAPIEN 3 in low-risk patients with aortic stenosis compared to surgery.

Edwards also shared results from its PARTNER Trial series at TCT, including the ten-year follow up of more than 3,000 intermediate-risk patients from PARTNER 2 (NCT01314313) and PARTNER 2 S3i, stating that these studies further demonstrated SAPIEN 3’s long-term valve performance and durability.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

According to GlobalData analysis, the TAVR market is growing at a CAGR of 7.1% and is forecast to reach a valuation of around $12.5bn by 2034, up from $6.3bn in 2024. A GlobalData market model reveals that Edwards held a commanding 75.1% US TAVR market share in 2024, eclipsing its nearest competitor, Medtronic, with market share of 20.8%.

Commenting on the data shared at TCT during its post-earnings conference call, Edwards’ CEO Bernard Zovighian commented: “This groundbreaking evidence sets a new global benchmark, one that is exceptionally reassuring for both patients and physicians.

“And its sets the stage for continued long-term adoption of SAPIEN to treat patients suffering from aortic stenosis.”

Elsewhere across its portfolio, Edwards reported a 59.3% uplift in its transcatheter mitral and tricuspid therapies (TMTT) product group, with revenue of $145.2m. Meanwhile, the surgical structural heart unit grew by 7.5% in Q3 2025 to $250m.

Zovighian highlighted in the earnings call that Edwards “comprehensive” portfolio of TMTT, which includes PASCAL precision repair system, EVOQUE tricuspid valve replacement system, and SAPIEN M3 mitral valve replacement system, is creating compounding value across the care continuum for all stakeholders.

“While the contribution to growth from our portfolio of repair and replacement therapy could vary by quarter or year, we know PASCAL, EVO and M3 will be key contributors as TMTT grows to an estimated $2bn by 2030,” Zovighian added.

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now